Cagatay Penbe, Susleyici-Duman Belgin, Ciftci Cavlan
Istanbul University, Cerrahpasa Faculty of Medicine Department of Biostatistics, Istanbul, Turkey.
Dis Markers. 2007;23(3):161-6. doi: 10.1155/2007/863712.
Our aim was to determine whether lipoprotein lipase gene PvuII polymorphism can be considered as an independent risk factor for coronary artery disease (CAD) by conducting a meta-analysis of all available published trials, including our own study. In 7 seperate studies, 3289 subjects were screened for this substitution; meta-analysis included only some of these individuals. Among the 7 studies, 6 were performed on white subjects, whereas 1 was on patients with Saudi Arabic descent.Subgroup analysis indicated that individuals with PvuII substitution does not have an increased risk for CAD. The LPL-PvuII genotype and allele frequency distributions did not differ significantly between CAD patients and healthy controls. There was no difference in the distribution of LPL-PvuII genotypes between the healthy subjects and the patients with CAD. However, no significant differences in lipid variables (triglyceride and HDL-cholesterol) were determined for the PvuII polymorphisms in the patients with CAD. No significant differences were found in serum triglyceride and HDL-cholesterol levels for LPL-PvuII genotypes when the control and CAD groups were pooled. In conclusion, LPL-Pvu II polymorphism cannot be used as independent genetic risk factor for CAD.
我们的目的是通过对所有已发表的可用试验（包括我们自己的研究）进行荟萃分析，来确定脂蛋白脂肪酶基因PvuII多态性是否可被视为冠状动脉疾病（CAD）的独立危险因素。在7项独立研究中，对3289名受试者进行了该替代位点的筛查；荟萃分析仅纳入了其中部分个体。在这7项研究中，6项是针对白人受试者开展的，而1项是针对沙特阿拉伯裔患者进行的。亚组分析表明，携带PvuII替代的个体患CAD的风险并未增加。CAD患者与健康对照之间的LPL - PvuII基因型和等位基因频率分布无显著差异。健康受试者与CAD患者之间的LPL - PvuII基因型分布也没有差异。然而，对于CAD患者中的PvuII多态性，脂质变量（甘油三酯和高密度脂蛋白胆固醇）未发现显著差异。将对照组和CAD组合并后，LPL - PvuII基因型的血清甘油三酯和高密度脂蛋白胆固醇水平未发现显著差异。总之，LPL - Pvu II多态性不能用作CAD的独立遗传危险因素。
